3,7,11,15-tetramethyl-hexadecan-1-ol Active Not Recruiting Phase 2 Trials for Acute Myelogenous Leukaemia (AML) Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01413880Alvocidib (Flavopiridol), Ara-C and Mitoxantrone (FLAM) Versus "7+3" for Newly (AML)